| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Versant Venture Capital VI, L.P. | 3.7% | -22% | $1,108,210 | -$13,298,570 | 162,972 | -92% | Versant Vantage II, L.P. | 11 Aug 2025 |
As of 30 Sep 2025, 1 institutional investors reported holding 269,772 shares of Tempest Therapeutics, Inc. - Common Stock, par value $0.001 per share (TPST). This represents 6.1% of the company’s total 4,404,649 outstanding shares.
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | 269,772 | $2,773,256 | $10.28 | 1 | |
| 2025 Q2 | 269,772 | $1,834,450 | +$4,518 | $6.80 | 1 |
| 2025 Q1 | 2,479,851 | $1,829,980 | -$3,627,308 | $0.74 | 21 |
| 2024 Q4 | 6,781,310 | $5,672,830 | +$2,859,183 | $0.83 | 34 |
| 2024 Q3 | 2,830,709 | $3,944,228 | +$794,366 | $1.40 | 29 |
| 2024 Q2 | 2,147,122 | $4,702,091 | +$383,804 | $2.19 | 23 |
| 2024 Q1 | 1,864,165 | $7,287,955 | -$1,486,471 | $3.91 | 28 |
| 2023 Q4 | 2,213,399 | $9,740,052 | +$8,694,542 | $4.40 | 32 |
| 2023 Q3 | 13 | $2 | -$279,773 | $0.15 | 1 |
| 2023 Q2 | 3,827,439 | $4,860,526 | +$899,834 | $1.27 | 22 |
| 2023 Q1 | 3,109,553 | $7,213,648 | +$110,262 | $2.32 | 16 |
| 2022 Q4 | 3,067,678 | $3,536,532 | -$23,289 | $1.15 | 13 |
| 2022 Q3 | 3,081,085 | $5,359,127 | -$82,167 | $1.74 | 14 |
| 2022 Q2 | 3,113,726 | $6,672,000 | +$2,166,245 | $2.14 | 15 |
| 2022 Q1 | 2,100,798 | $7,118,000 | -$1,240,492 | $3.38 | 13 |
| 2021 Q4 | 2,349,675 | $12,407,000 | -$1,465,941 | $5.28 | 16 |
| 2021 Q3 | 2,190,280 | $31,692,000 | +$5,237,555 | $14.47 | 19 |
| 2021 Q2 | 1,834,344 | $20,519,000 | +$20,515,991 | $11.18 | 19 |